Kuemmel, Sherko http://orcid.org/0000-0001-9355-494X
Tondini, Carlo A.
Abraham, Jacinta
Nowecki, Zbigniew
Itrych, Bartosz
Hitre, Erika
Karaszewska, Bogusława
Juárez-Ramiro, Alejandro
Morales-Vásquez, Flavia
Pérez-García, Jose Manuel
Cardona-Huerta, Servando
Monturus, Estefania
Sequi, Marco
Restuccia, Eleonora
Benyunes, Mark
Martín, Miguel
Clinical trials referenced in this document:
Documents that mention this clinical trial
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
https://doi.org/10.1007/s10549-021-06145-3
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd.
Article History
Received: 4 January 2021
Accepted: 8 February 2021
First Online: 21 March 2021
Compliance with ethical standards
:
: All authors received support for third-party writing assistance for this manuscript, provided by F. Hoffmann-La Roche Ltd. Professor Kümmel has received consulting fees from F. Hoffmann-La Roche Ltd, Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Somatex, Merck Sharp & Dohme, Pfizer, PUMA Biotechnology, and PFM Medical, and has received non-financial support outside the submitted work for a travel grant from F. Hoffmann-La Roche Ltd, Daiichi Sankyo, and SonoScape. Dr. Tondini has received an institutional grant from ASST Papa Giovanni XXIII for participation in the MetaPHER study, and institutional grants for participation in other clinical trials from F. Hoffmann-La Roche Ltd, Novartis, Merck Sharp & Dohme, Bristol Myers Squibb, AstraZeneca, and Array BioPharma, Inc. Dr. Abraham has received personal fees for conference participation from Eisai, and personal fees for an advisory board from Merck & Co, Inc. Dr. Nowecki has received a travel grant from F. Hoffmann-La Roche Ltd. Dr. Itrych has no other conflicts to disclose. Dr. Hitre has received research funding and non-financial support (i.e., drugs) outside the submitted work from F. Hoffmann-La Roche Ltd. Dr. Karaszewska has received research grants from F. Hoffmann-La Roche Ltd, Novartis, Merck & Co, Inc., and Amgen. Dr. Juárez-Ramiro has received fees for clinical research from F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Merck Sharp & Dohme, Bayer, Pfizer, and Amgen, and personal speaker fees from F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Merck Serono, Bayer, and Amgen. Dr. Morales-Vásquez has received consulting fees from F. Hoffmann-La Roche Ltd, AstraZeneca, and Asofarma. Dr. Pérez García has received personal fees for an advisory board and travel grants from F. Hoffmann-La Roche Ltd, and has received personal fees for an advisory board from Lilly. Dr. Cardona-Huerta has received consulting fees from F. Hoffmann-La Roche Ltd and AstraZeneca. Dr. Monturus is an employee of F. Hoffmann-La Roche Ltd (author and spouse/partner) and has stock/ownership interest in F. Hoffmann-La Roche Ltd/Genentech, Inc. (author and spouse/partner). Dr. Sequi is an employee of PAREXEL and is contracted by F. Hoffmann-La Roche Ltd. Dr. Restuccia is an employee of F. Hoffmann-La Roche Ltd and has stock/ownership interest in F. Hoffmann-La Roche Ltd. Dr. Benyunes is an employee of Genentech, Inc. Dr. Martín has received research grants and personal fees from F. Hoffmann-La Roche Ltd, PUMA, and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, F. Hoffmann-La Roche Ltd/Genentech, Inc., Novartis, PharmaMar, Eli Lilly, PUMA, Daiichi Sankyo, and Pfizer.
: The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Approval for the study protocol and all accompanying material provided to patients was obtained from independent ethics committees at participating institutions.
: All patients provided written informed consent.